TY - JOUR
T1 - L-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery disease
T2 - A multicenter, randomized, double-blind, placebo-controlled trial
AU - Goldenberg, Neil A.
AU - Krantz, Mori J.
AU - Hiatt, William R.
PY - 2012/6
Y1 - 2012/6
N2 - Intermittent claudication (IC) is the predominant symptom of peripheral artery disease (PAD), and is associated with reduced exercise capacity. The pathophysiology of IC is related to reduced blood flow and impaired skeletal muscle oxidative metabolism; however, the efficacy of metabolic therapies is not well established. We evaluated the effect of cilostazol plus l-carnitine versus cilostazol alone on exercise performance, quality of life (QOL), and safety. In a double-blind, placebo-controlled trial, PAD patients with stable IC were randomized to either l-carnitine 1 g or matching placebo twice-daily, on a background of cilostazol. Treadmill and QOL assessments were performed at baseline, 90, and 180 days. The primary endpoint was the difference between groups in the natural-log-transformed (ln) ratio in peak walking time (PWT) between baseline and 180 days. The combination of cilostazol and l-carnitine was well tolerated. In the modified intent-to-treat population (n = 145), the mean ln ratio in PWT was 0.241 for cilostazol/l-carnitine versus 0.134 for cilostazol/placebo (p = 0.076), corresponding to mean increases of 1.99 and 1.36 minutes, respectively. In the per-protocol population (n = 120), the mean ln ratio in PWT was 0.267 for cilostazol/l-carnitine versus 0.145 for cilostazol/placebo (p = 0.048). QOL measures were also improved in the cilostazol/l-carnitine group. These findings support larger trials of l-carnitine in combination with cilostazol in the treatment of IC.
AB - Intermittent claudication (IC) is the predominant symptom of peripheral artery disease (PAD), and is associated with reduced exercise capacity. The pathophysiology of IC is related to reduced blood flow and impaired skeletal muscle oxidative metabolism; however, the efficacy of metabolic therapies is not well established. We evaluated the effect of cilostazol plus l-carnitine versus cilostazol alone on exercise performance, quality of life (QOL), and safety. In a double-blind, placebo-controlled trial, PAD patients with stable IC were randomized to either l-carnitine 1 g or matching placebo twice-daily, on a background of cilostazol. Treadmill and QOL assessments were performed at baseline, 90, and 180 days. The primary endpoint was the difference between groups in the natural-log-transformed (ln) ratio in peak walking time (PWT) between baseline and 180 days. The combination of cilostazol and l-carnitine was well tolerated. In the modified intent-to-treat population (n = 145), the mean ln ratio in PWT was 0.241 for cilostazol/l-carnitine versus 0.134 for cilostazol/placebo (p = 0.076), corresponding to mean increases of 1.99 and 1.36 minutes, respectively. In the per-protocol population (n = 120), the mean ln ratio in PWT was 0.267 for cilostazol/l-carnitine versus 0.145 for cilostazol/placebo (p = 0.048). QOL measures were also improved in the cilostazol/l-carnitine group. These findings support larger trials of l-carnitine in combination with cilostazol in the treatment of IC.
KW - cilostazol
KW - claudication
KW - peak walking time
KW - peripheral artery disease
KW - placebo
UR - http://www.scopus.com/inward/record.url?scp=84861815980&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84861815980&partnerID=8YFLogxK
U2 - 10.1177/1358863X12442264
DO - 10.1177/1358863X12442264
M3 - Article
C2 - 22615190
AN - SCOPUS:84861815980
SN - 1358-863X
VL - 17
SP - 145
EP - 154
JO - Vascular Medicine (United Kingdom)
JF - Vascular Medicine (United Kingdom)
IS - 3
ER -